|
|||||
|
|
In vivo release of anti-Xa clotting activity by a heparin analogue |
|
| Authors: | D.P. Thomas T.W. Barrowcliffe R.E. Merton J. Stocks J. Dawes D.S. Pepper |
| Affiliation: | * National Institute for Biological Standards and Control, Holly Hill, Hampstead, London, UK + St. Bartholomew's Hospital, West Smithfield, London, UK † MRC Immunoassay Team, 2 Forrest Road, Edinburgh, UK § Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh, UK |
| Abstract: | The parenteral injection of a semi-synthetic heparin analogue (SSHA) releases anti-Xa clotting activity, lipoprotein lipase activity and PF4 antigen. The increased anti-Xa activity is not neutralized by PF4 or protamine sulphate. A second injection of the drug after 90 minutes, or an increase in dose, does not increase the level of induced anti-Xa clotting activity. Possible mechanisms of action include the release by SSHA of endogenous glycosaminoglycans with anti-Xa activity, and interference by released lipoprotein lipase of a modulator of anti-Xa activity. It is concluded that a drug with weak anticoagulant activity in vitro may nevertheless have significant antithrombotic potential. |
| Keywords: | Author Keywords: Heparin analogue anti-Xa heparin in vivo release PF4 |
| 本文献已被 ScienceDirect 等数据库收录！ | |